Gene therapy for the extension of vein graft patency: A review

Vascular and Endovascular Surgery

Volumn 39, Issue 1, 2005, Pages 1-14

  Chandiwal, Amito ^a   Balasubramanian, Viji ^a,b   Baldwin, Zachary K ^a   Conte, Michael S ^c   Schwartz, Lewis B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Illinois Institute of Technology   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BASIC FIBROBLAST GROWTH FACTOR; BETA ADRENERGIC RECEPTOR; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE 1; CYCLIN G1; CYCLINE; ELONGATION FACTOR 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HERPESVIRUS VECTOR; HIRUDIN; MYC PROTEIN; NATRIURETIC PEPTIDE TYPE C; PARVOVIRUS VECTOR; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR A; PROTEIN C MYB; PROTEIN FARNESYLTRANSFERASE; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR E2F; UTEROGLOBIN; VASCULOTROPIN;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DNA MODIFICATION; GENE THERAPY; GRAFT PATENCY; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVASCULAR ULTRASOUND; NONHUMAN; PERIPHERAL VASCULAR DISEASE; RABBIT; REVIEW; TRANSGENE; VASCULAR SMOOTH MUSCLE; VEIN GRAFT;

ARTERIAL OCCLUSIVE DISEASES; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; MUSCLE, SMOOTH, VASCULAR; TUNICA INTIMA; VASCULAR PATENCY; VEINS;

EID: 13244264668     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440503900101     Document Type: Review

References (175)

1. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349:1269-1276, 1997.
2. Leng GC, Papacosta O, Whincup P, et al: Femoral atherosclerosis in an older British population: Prevalence and risk factors. Atherosclerosis 152:167-174, 2000.
3. Regensteiner JG, Hiatt WR: Current medical therapies for patients with peripheral arterial disease: A critical review. Am J Med 112:49-57, 2002.
4. Criqui MH, Fronek A, Barrett-Connor E, et al: The prevalence of peripheral arterial disease in a defined population. Circulation 71:510-515, 1985.
5. Newman AB: Peripheral arterial disease: Insights from population studies of older adults. J Geriatr Soc 48:1157-1162, 2000.
6. Nehler MR, McDermott MM, Treat-Jacobson D, et al: Functional outcomes and quality of life in peripheral arterial disease: Current status. Vasc Med 8:115-126, 2003.
7. Ouriel K: Peripheral arterial disease. Lancet 358:1257-1264, 2001.
8. Gray BH, Sullivan TM, Childs MB, et al: High incidence of restenosis/reocclusion of intravascular stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 25:74-83, 1997.
9. Gray B, Olin J: Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusive disease. Semin Vasc Surg 10:8-16, 1997.
10. Hewes RC, White RI Jr, Murray RR, et al: Long-term results of superficial femoral artery angioplasty. Am J Roentgenol 146:1025-1029, 1986.
11. Capek P, McLean G, Berkowitz H: Femoropopliteal angioplasty: Factors influencing long-term success. Circulation 83(suppl 1):70-80, 1991.
12. Karch L, Mattos M, Henretta J, et al: Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries. J Vasc Surg 31:880-887, 2000.
13. Rutkow IM, Ernst CB: An analysis of vascular surgical manpower requirements in the United States. J Vasc Surg 3:74-83, 1986.
14. Whittemore AD, Donaldson MC, Mannick JA: Ten-year patency of autogenous vein bypass grafts. In: Long-term Results in Vascular Surgery, ed. by Yao JST, Pearce WH. Norwalk: Appleton & Lange, 1993, pp 243-246.
15. Conte MS, Belkin M, Upchurch G, et al: Impact of increasing comorbidity on infrainguinal reconstruction: A 20-year perspective. Ann Surg 253:445-452, 2001.
16. Donaldson MC, Whittemore AD, Mannick JA: Further experience with an all-autogenous tissue policy for infrainguinal reconstruction. J Vasc Surg 18:41-48, 1993.
17. Bergamini TM, George SM Jr, Massey HT, et al: Intensive surveillance of femoropopliteal-tibial autogenous vein bypasses improves long-term graft patency and limb salvage. Ann Surg 221:507-516, 1995.
18. Veith FJ, Gupta SK, Ascer E, et al: Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 3:104-114, 1986.
19. Olojugba DH, McCarthy MJ, Reid A, et al: Infrainguinal revascularisation in the era of veingraft surveillance-Do clinical factors influence long-term outcome? Eur J Vasc Endovasc Surg 17:121-128, 1999.
20. Johnson WC, Lee KK: A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoro-popliteal above-knee revascularization: A prospective randomized Department of Veterans Affairs cooperative study. J Vasc Surg 32:268-277, 2000.
21. Hölzenbein T, Pomposelli F, Miller A, et al: Results of a policy with arm veins used as the first alternative to an unavailable ipsilateral greater saphenous vein for infrainguinal bypass. J Vasc Surg 23:130-140, 1996.
22. Donaldson MC, Mannick JA, Whittemore AD: Femoral-distal bypass with in-situ greater saphenous vein: Long-term results using the Mills valvulotome. Ann Surg 213:457-465, 1991.
23. Watelet J, Soury P, Menard J-F, et al: Femoropopliteal bypass: In situ or reversed vein grafts? Ten-year results of a randomized prospective study. Ann Vasc Surg 11:510-519, 1997.
24. Anderson CB, Stevens SL, Allen BT, et al: In situ saphenous vein for lower extremity revascularization. Surgery 112:6-10, 1992.
25. Curi MA, Skelly CL, Desai TR, et al: Conduit choice for above-knee femoropopliteal grafting in patients with limb-threatening ischemia. Ann Vasc Surg 16:95-101, 2002.
26. Jamsen T, Tulla H, Manninen H, et al: Results of infrainguinal bypass surgery: An analysis of 263 consecutive operations. Ann Chir Gynaecol 90:92-99, 2001.
27. Rossi PJ, Skelly CL, Meyerson SL, et al: Redo infrainguinal bypass: Factors predicting patency and limb salvage. Ann Vasc Surg 17:492-502, 2003.
28. Klamer TW, George SM Jr, Lambert GE: Ten year experience with infrainguinal revascularization for limb salvage. J Ky Med Assoc 94:270-277, 1996.
29. Robinson KD, Sato DT, Gregory RT, et al: Long-term outcome after early infrainguinal graft failure. J Vasc Surg 26:425-438, 1997.
30. Nasr MK, McCarthy RJ, Budd JS, et al: Infrainguinal bypass graft patency and limb salvage rates in critical limb ischemia: Influence of the mode of presentation. Ann Vasc Surg 17:192-197, 2003.
31. Douglas JS, Weintraub WS, Holmes D: Rationale and design of the randomized, multicenter, Cilostazol for RESTenosis (CREST) Trial. Clin Cardiol 26:451-454, 2003.
32. Hogrefe R: An antisense oligonucleotide primer. Antisense Nucl Acid Drug Dev 9:351-357, 1999.
33. Suzuki T, Kopia G, Hayashi S-I, et al: Stent-based delivery of Sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193, 2001.
34. Curi MA, Huang W, Woo DH, et al: Brief intraluminal exposure to attenuated Herpes simplex virus-1 alters the arterial remodeling response to extremely low shear stress (abstract). J Am Coll Surg 195: S97, 2002.
35. Terashima M, Grube E, Takahashi T, et al: Intraoperative cell-cycle blockade using E2F decoy for prevention of early atherosclerosis in coronary bypass vein graft: A volumetric IVUS subanalysis from a prospective randomized double blind clinical trial. J Am Coll Cardiol 39:228A, 2002.
36. Eton D, Yu H, Wang Y, et al: Endograft technology: A delivery vehicle for intravascular gene therapy. J Vasc Surg 39:1066-1073, 2004.
37. Conte MS, Mann MJ, Simosa HF, Rhynhart KK, Mulligan RC. Genetic interventions for vein bypass graft disease: A review. J Vasc Surg 36:1040-1052, 2002.
38. Sirois MG, Simons M, Edelman ER: Antisense oligonucleotide inhibition of PDGFR-B receptor subunit expression directs suppression of intimal thickening. Circulation 95:669-676, 1997.
39. Baldwin ZK, Pearce BJ, Curi MA, et al: Long-term prognosis following infrainguinal bypass graft failure. J Vasc Surg 39:951-957, 2004.
40. Meyerson SL, Moawad J, Loth F, et al: Effective hemodynamic diameter: An intrinsic property of vein grafts with predictive value for patency. J Vasc Surg 31:910-917, 2000.
41. Wengerter KR, Vieth FJ, Gupta SK, et al: Influence of vein size (diameter) on infrapopliteal reversed vein graft patency. J Vasc Surg 11:525-531, 1990.
42. Skelly CL, Meyerson SL, Curi MA, et al: The hemodynamics of vein grafts: Measurement and meaning. Ann Vasc Surg 15:110-122, 2001.
43. Idu M, Buth J, Hop W, et al: Factors influencing the development of vein-graft stenosis and their significance for clinical management. Eur J Vasc Endovasc Surg 17:15-21, 1999.
44. Schwartz LB, Belkin M, Donaldson MC, et al: Validation of a new and specific intraoperative measurement of vein graft resistance. J Vasc Surg 25:1033-1043, 1997.
45. Schwartz LB, Purut CM, Craig DM, et al: Measurement of vascular input impedance in infrainguinal vein grafts. Ann Vasc Surg 11:35-43, 1997.
46. Clowes AW, Reidy MA, Clowes MM: Kinetics of cellular proliferation after injury: I. Smooth muscle growth in the absence of endothelium. Lab Invest 49:327-333, 1983.
47. Han C, Campbell GR, Campbell JH: Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 38:113-119, 2001.
48. Schwartz SM, O'Brien ER, de Blois D, et al: Relevance of smooth muscle replication and development to vascular disease. In: The Vascular Smooth Muscle Cell: Molecules and Biological Responses to The Extracellular Matrix, ed. by Schwartz SM, Mecham RP. San Diego: Academic Press, 1995, pp 81-139.
49. Shi Y, O'Brien JE, Fard A, et al: Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 94:1655-1664, 1996.
50. Zalewski A, Shi Y, Johnson AG: Diverse origin of intimal cells. Smooth muscle cells, myofibroblasts, fibroblasts, and beyond? Circ Res 91:652-655, 2002.
51. Schwartz RS, Holmes DR Jr, Topol EJ: The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol 20:1284-1293, 1992.
52. Mills I, Letsou G, Rabban J, et al: Mechanosensitive adenylate cyclase activity in coronary vascular smooth muscle cells. Biochem Biophys Res Commun 171:143-147, 1990.
53. Curi MA, Skelly CL, Meyerson SL, et al: Differential activation of MAPK signal transduction in intact human artery and vein. J Surg Res 108:198-202, 2002.
54. Sumpio BE, Banes AJ, Link WG, et al: Enhanced collagen production by smooth muscle cells during repetitive mechanical stretching. Arch Surg 123:1233-1236, 1988.
55. Schwartz LB, O'Donohoe MK, Mikat EM, et al: Effects of distention and short-term grafting on vasoreactivity in rabbit external jugular veins. Surgery 110:146-153, 1991.
56. Schwartz LB, Purut CM, Massey MF, et al: Effects of pulsatile perfusion on human saphenous vein vasoreactivity. Cardiovasc Surg 4:143-149, 1995.
57. Schwartz LB, O'Donohoe MK, Purut CM, et al: Myointimal thickening in experimental vein grafts is dependent on wall tension. J Vasc Surg 15:176-186, 1992.
58. Dobrin PB, Littooy FN, Endean ED: Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. Surgery 105:393-400, 1989.
59. Adcock OT, Adcock GL, Wheeler JR, et al: Optimal techniques for harvesting and preparation of reversed autogenous vein grafts for use as arterial substitutes. Surgery 96:886-893, 1984.
60. Brody WR, Kosek JC, Angell EE: Changes in vein grafts following aorto-coronary bypass induced by pressure and ischemia. J Thorac Cardiovasc Surg 64:847-854, 1972.
61. Brody WR, Angell WW, Kosek JC: Histologic fate of the venous coronary artery bypass in dogs. Am J Pathol 66:111-130, 1972.
62. Kohler TR, Kirkman TR, Clowes AW: The effect of rigid external support on vein graft adaptation to the arterial circulation. J Vasc Surg 9:277-285, 1989.
63. Fann JL, Sokoloff MH, Sarris GE, et al: The reversibility of canine vein graft arterialization. Circulation 82(suppl IV):9-18, 1990.
64. Sterpetti AV, Cucina A, Lepidi S, et al: Progression and regression of myointimal hyperplasia in experimental vein grafts depends on platelet-derived growth factor and basic fibroblast growth factor production. J Vasc Surg 23:568-575, 1996.
65. Davies MG, Fulton GJ, Svendsen E, et al: Time course of the regression of intimal hyperplasia in experimental vein grafts. Cardiovasc Pathol 8:161-168, 1999.
66. Zarins CK, Zatina MA, Giddens DP, et al: Shear stress regulation of artery lumen diameter in experimental atherogenesis. J Vasc Surg 5:413-420, 1987.
67. Zhuang YJ, Singh TM, Zarins CK, et al: Sequential increases and decreases in blood flow stimulates progressive intimal thickening. Eur J Vasc Endovasc Surg 16:301-310, 1998.
68. Gnasso A, Carallo C, Irace C, et al: Association between intima-media thickness and wall shear stress in common carotid arteries in healthy male subjects. Circulation 94:3257-3262, 1996.
69. Hehrlein C, Chuang CH, Tuntelder JR, et al: Effects of vascular runoff on myointimal hyperplasia after mechanical balloon or thermal laser arterial injury in dogs. Circulation 1991:884-890, 1991.
70. Zarins CK, Giddens DP, Bharadvaj BK, et al: Carotid bifurcation atherosclerosis: Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res 53:502-514, 1983.
71. Morinaga K, Okadome K, Kuroki M, et al: Effect of wall shear stress on intimal thickening of arterially transplanted autogenous veins in dogs. J Vasc Surg 2:430-433, 1985.
72. Kohler TR, Kirkman TR, Kraiss LW, et al: Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts. Circ Res 69:1557-1565, 1991.
73. Faulkner SL, Fisher RD, Conkle DM, et al: Effect of blood flow rate on subendothelial proliferation in venous autografts used as arterial substitutes. Circulation 51/52(suppl 1):162-172, 1975.
74. Bond MG, Hostetler JR, Karayannacos PE, et al: Intimal changes in arteriovenous bypass grafts-effects of varying the angle of implantation at the proximal anastomosis and of producing stenosis in the distal runoff artery. J Thorac Cardiovasc Surg 71:907-916, 1976.
75. Rittgers SE, Karayannacos PE, Guy JF, et al: Velocity distribution and intimal proliferation in autologous vein grafts in dogs. Circ Res 42:792-801, 1978.
76. Shin CS, Hatem JN, Abach IF: Effects of diminished distal blood flow on the morphologic changes in autogenous vein grafts. Surg Gynecol Obstet 147:189-192, 1978.
77. Karayannacos PE, Rittgers SE, Kakos GS, et al: Potential role of velocity and wall tension in vein graft failure. J Cardiovasc Surg 21:171-178, 1980.
78. Berguer R, Higgins RF, Reddy DJ: Intimal hyperplasia: An experimental study. Arch Surg 115:332-335, 1980.
79. Meyerson SL, Skelly CL, Curi MA, et al: The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft. J Vasc Surg 34:90-97, 2001.
80. Baldwin ZK, Chandarwal A, Balasubramainian V, et al: Modulation of vascular remodeling induced by a brief intraluminal exposure to the recombinant R7020 strain of Herpes simplex-1. William J. von Liebig Award for Vascular Research (submitted).
81. Nabel EG, Plautz G, Boyce FM, et al: Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 244:1342-1344, 1989.
82. Riessen R, Rahimizadeh H, Blessing E, et al: Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther 4:749-758, 1993.
83. Isner JM: Therapeutic angiogenesis: A new frontier for vascular therapy. Vasc Med 1:79-87, 1996.
84. Indolfi C, Awedimento EV, Rapacciuolo A, et al: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1:541-545, 1995.
85. Ludwig S, Rapp UR: Cascading towards vascular disorder gene therapy. Nat Med 1995:513-515, 1995.
86. Shyy JY, Jin G, Li Y-S, et al: The use of rasN17 in gene therapy to prevent artery restenosis (abstract). Circulation 96(suppl I):I-669, 1997.
87. Kalra M, Jost CJ, Severson SR, et al: Adventitial versus intimal liposome-mediated ex vivo transfection of canine saphenous vein grafts with endothelial nitric oxide synthase gene. J Vasc Surg 32:1190-1200, 2000.
88. Keogh MC, Chen D, Lupu F, et al: High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid-DNA complex. Gene Ther 4:162-171, 1997.
89. Matsumoto T, Komori K, Yonemitsu Y, et al: Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 27:135-144, 1998.
90. Armeanu S, Pelisek J, Krausz E, et al: Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol Ther 1:366-375, 2000.
91. Kalra M, Jost CJ, Severson SR, et al: Adventitial versus intimal liposome mediated ex vivo transfection of canine saphenous vein grafts with endothelial nitric oxide synthase gene. J Vasc Surg 32:1190-2000, 2000.
92. Rolling F, Nong Z, Pisvin S, et al: Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Ther 4:757-761, 1997.
93. Lynch CM, Hara PS, Leonard JC, et al: Adeno-associated virus vectors for vascular gene delivery. Circ Res 80:497-505, 1997.
94. Kotin RM: Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 5:793-801, 1994.
95. Xiao X, Li J, Samulski RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70:8098-8108, 1996.
96. Svensson EC, Marshall DJ, Woodard K, et al: Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 99:201-205, 1999.
97. Eslami MH, Gangadharan SP, Sui XX, et al: Gene delivery to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors. J Vasc Surg 31:1149-1159, 2000.
98. Chang MW, Barr E, Seltzer J, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267:518-522, 1995.
99. Chang MW, Barr E, Lu MM, et al: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 95:2260-2268, 1995.
100. Hong-zhi B, Yoshiki S, Tomoyuki Y, et al: Gene transfer of senescent cell-derived inhibitor 1 into vein graft inhibited neointimal hyperplasia in vivo associated with induction of smooth muscle cell redifferentiation. Circulation 92(suppl I):I-642, 1995.
101. Fulton GJ, Davies MG, Lefkowitz RJ, et al: Transfection with ßARKCT reduces intimal hyperplasia in experimental vein grafts. Surg Forum 47:341-345, 1996.
102. Hanna AK, Fox JC, Neschis DG, et al: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 25:320-325, 1997.
103. Matsushita H, Morishita R, Kida I, et al: Inhibition of growth of human vascular smooth muscle cells by overexpression of p21 gene through induction of apoptosis. Hypertension 31(1 Pt 2):493-498, 1998.
104. Neschis DG, Safford SD, Hanna AK, et al: Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. J Vasc Surg 27:126-134, 1998.
105. Ueno H, Haruno A, Morisaki N, et al: Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 96:2272-2279, 1997.
106. Quax PHA, Lamfers ML, Grimbergen JG, et al: Inhibition of neointima formation in cultured human saphenous vein segments by an adenovirus expressing a urokinase receptor binding plasmin inhibitor (abstract). Circulation 96(suppl I):I-669, 1997.
107. Smith RC, Wills KN, Antelman D, et al: Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation 96:1899-1905, 1997.
108. Schwartz LB, Moawad J, Svensson EC, et al: Adenoviral-mediated transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vasc Surg 29:874-883, 1999.
109. Svensson EC, Schwartz LB: Gene therapy for vascular disease. Curr Opin Cardiol 13:369-374, 1998.
110. Meyerson SI, Xin S, Schwartz LB: Gene therapy as a therapeutic intervention for vascular disease. J Cardiovasc Nurs 13:91-109, 1999.
111. Cheng L, Mantile G, Pauly R, et al: Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 98:2195-2201, 1998.
112. Varenne O, Pislaru S, Gillikns H, et al: Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 98:919-926, 1998.
113. Cable DG, Caccitolo JA, Caplice N, et al: The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 100(suppl II):II392-II396, 1999.
114. George SJ, Lloyd CT, Angelini GD, et al: Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101:296-304, 2000.
115. Ascher E, Scheinman M, Hingorani A, et al: Effect of p53 gene therapy combined with CTLA4Ig selective immunosuppression on prolonged neointima formation reduction in a rat model. Ann Vasc Surg 14:385-392, 2000.
116. Bishop GG, Wiegman P, McNamara C, et al: Local adenovirus-mediated delivery of hirudin in a rabbit arterial injury model. J Vasc Res 36:343-352, 1999.
117. Dollery CM, Humphries SE, McClelland A, et al: Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointima hyperplasia in the rat model of vascular balloon injury. Circulation 99:3199-3205, 1999.
118. Scheinman M, Asher E, Levi GS, et al: p53 gene transfer to the injured rat carotid artery decreases neointimal formation. J Vasc Surg 29:360-369, 1999.
119. Waugh JM, Li-Hawkins J, Yuksel E, et al: Thrombomodulin overexpression to limit neointima formation. Circulation 102:332-337, 2000.
120. Sharma RV, Tan E, Fang S, et al: NOS gene transfer inhibits expression of cell cycle regulatory molecules in vascular smooth muscle cells. Am J Physiol 276:H1450-1459, 1999.
121. Larson RA, Naji M, Lombardi JV, et al: Adenoviral-mediated uteroglobin gene transfer inhibits neointimal hyperplasia after balloon injury in the rat carotid artery. J Vasc Surg 32:1111-1117, 2000.
122. Huynh TTT, Iaccarino G, Davies MG, et al: Adenoviral-mediated inhibition of GBg signaling limits the hyperplastic response in experimental vein grafts. Surgery 124:177-186, 1998.
123. Quax PHA, Lamfers MLM, Lardenoye JHP, et al: Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 103:562-569, 2001.
124. Atsuchi N, Nishida T, Marutsuka K, et al: Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 103:570-575, 2001.
125. McArthur JG, Qian H, Citron D, et al: p27-p16 chimera: A superior antiproliferative for the prevention of neointimal hyperplasia. Mol Ther 3:8-13, 2001.
126. Hiltunen MO, Laitinen M, Turunen MP, et al: Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointimal formation in balloon-denuded rabbit aorta. Circulation 102:2262-2268, 2000.
127. Zhu NL, Wu L, Liu PX, et al: Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 96:628-635, 1997.
128. Miyatake S-I, Yukawa H, Toda H, et al: Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus. Stroke 30:2431-2438, 1999.
129. Skelly CL, Curi MA, Meyerson SL, et al: Prevention of restenosis by a Herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo. Gene Ther 8:1840-1846, 2001.
130. Curi MA, Skelly CL, Meyerson SL, et al: Sustained inhibition of experimental neointimal hyperplasia using a genetically modified herpes simplex virus. J Vasc Surg 37:1294-1300, 2003.
131. Morishita R, Gibbons GH, Ellison KE, et al: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci 90:8474-8478, 1993.
132. Mann MJ, Gibbons GH, Hutchinson H, et al: Effective antisense oligonucleotide transfection in human saphenous vein for the development of genetically engineered bypass grafts. Circulation 92(suppl I):I-642, 1995.
133. Mann MJ, Gibbons GH, Kernoff RS, et al: Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci 92:4502-4506, 1995.
134. Shi Y, Fard A, Galeo A, et al: Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injuiy. Circulation 90:944-951, 1994.
135. Kipshidze NN, Kim H, Iversen P, et al: Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol 39:1686-1691, 2002.
136. Pitsch RJ, Goodman GR, Minion DJ, et al: Inhibition of smooth muscle cell proliferation and migration in vitro by antisense oligonucleotide to c-myb. J Vasc Surg 23:783-791, 1996.
137. Jin G, Wu JC, Li Y-S, et al: Effects of active and negative mutants of ras on rat arterial neointima formation. J Surg Res 94:124-132, 2000.
138. Chemla E, Gastier Y, Julia P, et al: Inhibition of intimal hyperplasia by an antisense oligonucleotide of farnesyl transferase delivered endoluminally during iliac angioplasty in a rabbit model. Ann Vasc Surg 11:581-587, 1997.
139. Lund DD, Faraci FM, Miller FJJ, et al: Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits. Circulation 101:1027-1033, 2000.
140. Mann MJ, Whittemore AD, Donaldson MC, et al: Preliminary clinical experience with genetic engineering of human vein grafts: Evidence for target gene inhibition (abstract). Circulation 96(suppl I):I-4, 1997.
141. Mann MJ, Whittemore AD, Donaldson MC, et al: Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomized controlled trial. Lancet 354:1493-1498, 1999.
142. Isner JM, Walsh K, Symes J, et al: Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 91:2687-2692, 1995.
143. Baumgartner I, Pieczek A, Manor O, et al: Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123, 1998.
144. Nabel G, Nabel EG: Recombinant gene transfer: Scientific insights, disease pathogenesis, and its potential to treat human disease. J Vasc Surg 24:148-149, 1996.
145. Kozarsky KF, Wilson JM: Gene therapy: Adenovirus vectors. Curr Opin Gen Dev 3:499-503, 1993.
146. Brenner M: Reports of adenovector "death" are greatly exaggerated. Mol Ther 1:205, 2000.
147. Moawad J, Leiden JM, Meyerson SI, et al: Adenoviral-mediated gene transfer in experimental vein grafts using clinically-relevant exposure times, pressures, and viral concentrations. Ann Vasc Surg 15:367-373, 2001.
148. Schulick AH, Dong G, Newman KD, et al: Endothelium-specific in vivo gene transfer. Circ Res 77:475-485, 1995.
149. Steg PG, Feldman LJ, Scoazec J, et al: Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 90:1648-1656, 1994.
150. Marshall DJ, Palasis M, Lepore JJ, et al: Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: An important determinant of the efficiency of cardiovascular gene transfer. Mol Ther 1:423-429, 2000.
151. Schwartz LB, Pence JC, Kerns BJ, et al: Kinetics of experimental vein graft cell division and function. Surg Forum 27:363-365, 1991.
152. Golden MA: Modification of vein graft adaptation using adenoviral vectors. J Vasc Surg 24:161-163, 1996.
153. Huber TS, Welling TH, Sarkar R, et al: Effects of retroviral-mediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluroethylene. J Vasc Surg 22:795-803, 1995.
154. Channon KM, Fulton GJ, Gray JL, et al: Efficient adenoviral gene transfer to early venous bypass grafts: Comparison with native vessels. Cardiovasc Res 35:505-513, 1997.
155. West NEJ, Qian H, Tuzik T, et al: Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 104:1526-1532, 2001.
156. George SJ, Angelini GD, Capogrossi MC, et al: Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 8:668-676, 2001.
157. Kibbe MR, Nie S, Yoneyama T, et al: Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts. Surgery 26:323-329, 1999.
158. Kibbe MR, Tzeng E, Gleixner SL, et al: Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 34:156-165, 2001.
159. Fulton GJ, Davies MG, Koch WJ, et al: Antisense oligonucleotide to proto-oncogene c-myb inhibits the formation of intimal hyperplasia in experimental vein grafts. J Vasc Surg 25:453-463, 1997.
160. Fulton GJ, Davies MG, Barber L, et al: Locally applied antisense oligonucleotide to proliferating cell nuclear antigen inhibits intimal thickening in experimental vein grafts. Ann Vasc Surg 12:412-417, 1998.
161. Hanna AK, Durán WN, Leconte I, et al: Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts. J Vasc Surg 31:770-780, 2000.
162. Bai H, Morishita R, Kida I, et al: Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther 5:761-769, 1998.
163. Nakano K, Todo T, Chijiiwa K, et al: Therapeutic efficacy of G207, a conditionally replicating Herpes simplex virus type I mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol Ther 3:431-437, 2001.
164. Wolfe D, Coins WF, Kaplan TJ, et al: Herpesvirus-mediated systemic delivery of nerve growth factor. Mol Ther 3:61-69, 2001.
165. Chou J, Roizman B: Herpes simplex virus 1 gamma-1 34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci 91:5247-5251, 1994.
166. Oyama M, Ohigashi T, Hoshi M, et al: Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. J Urol 165:1274-1278, 2001.
167. Luna MC, Chen X, Wong S, et al: Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter. Cancer Res 62:1458-1461, 2002.
168. Morishita R, Gibbons GH, Horiuchi M, et al: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci 92:5855-5859, 1995.
169. Nakamura T, Morishita R, Asai T, et al: Molecular strategy using cis-element "decoy" of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 9:488-494, 2002.
170. Kawauchi M, Suzuki J, Wada Y, et al: Downregulation of nuclear factor kappa B expression in primate cardiac allograft arteries after E2F decoy transfection. Trans Proc 33:451, 2001.
171. Kawauchi M, Suzuki J, Morishita R, et al: Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 87:1063-1068, 2000.
172. Ehsan A, Mann MJ, Dell'Acqua G, et al: Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121:714-722, 2001.
173. Weintraub S, Prater C, Dean D: Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358:259-261, 1992.
174. Hedman M, Hartikainen J, Syvänne M, et al: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the
175. Kutryk MJB, Foley DP, Brand M, et al: Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis. Results of the randomized investigation by the thorax center of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) Trial. J Am Coll Cardiol 39:281-287, 2002.